KOEDA Inc., Developing Next-Generation Anchor Stents Revolutionizing Endoscopic Treatment, Raises New Funds from Mitsubishi UFJ Capital
KOEDA Inc., a developer of next-generation endoscopic treatment devices using innovative "anchor technology," has secured new funding from Mitsubishi UFJ Capital, following additional investment from Tohoku University Venture Partners. This capital will accelerate domestic clinical trials and US market entry, aiming for an M&A exit by 2030.
📋 Article Processing Timeline
- 📰 Published: March 31, 2026 at 21:00
- 🔍 Collected: April 1, 2026 at 13:39 (16h 39m after Published)
- 🤖 AI Analyzed: April 17, 2026 at 00:02 (370h 23m after Collected)
KOEDA Inc. (Headquarters: Sendai City, Aoba Ward, Miyagi Prefecture; Representatives: Toru Okuzono / Masahiro Yagi, hereinafter 'KOEDA'), which develops next-generation endoscopic treatment devices, is pleased to announce that it has completed a third-party allotment of new shares with Mitsubishi UFJ Capital Co., Ltd. (hereinafter 'MUCAP') as the underwriter, in addition to additional investment from existing investor Tohoku University Venture Partners Co., Ltd.
■ Background and Purpose of Funding: Accelerating domestic investigational clinical trials and US expansion
In 2025, KOEDA successfully completed First in Human (FIH) trials, considered the biggest hurdle in medical device development, proving the safety for clinical application in humans.
The funds raised this time will be used to accelerate the following business progress:
1. Conducting domestic investigational clinical trials: Completion of clinical trials for early manufacturing and sales approval and insurance coverage.
2. Strengthening regulatory affairs application and Quality Management System (QMS): Building a system for domestic launch and US FDA approval application.
3. Preparation for global expansion: Acquiring FDA approval and strengthening intellectual property strategy with an eye on entering the US market, our largest target.
■ About KOEDA Inc.: Transforming Digestive Medicine with the World's First 'Anchor Technology'
KOEDA is a startup developing endoscopic treatment devices (drainage for EUS-GBD/GJ) using the world's first 'anchor technology' for digestive diseases, including acute cholecystitis.
1. KOEDA's Ingenuity: Our proprietary 'anchor mechanism' physically secures organs. This simplifies procedures for digestive diseases like acute cholecystitis, shortens procedure times, and dramatically reduces the risk of complications.
2. High Technical Reliability: Having been selected multiple times for public funding such as AMED (Seeds A/C/Medical-Engineering Collaboration) and JST START, and having received the Japan Biliary Association Award, KOEDA has earned extremely high evaluations from specialized institutions and Key Opinion Leaders (KOLs).
■ Future Outlook: Roadmap Aiming for M&A EXIT by 2030
Leveraging this funding round, KOEDA aims to achieve the following milestones and pursue an M&A exit to a global med-tech company by 2030.
2027-2028: Obtain manufacturing and sales approval in Japan and launch. Introduction to major hospitals after insurance coverage.
2029: Obtain US FDA approval. Commence sales in the global market.
2030: Expand indications from gallbladder drainage (EUS-GBD) to gastrojejunostomy (EUS-GJ) and achieve business sale (M&A).
■ KOEDA Inc. Company Overview
Company Name: KOEDA Inc.
Representative: Toru Okuzono (Graduate of Tohoku University School of Medicine, Chief Director of Gastroenterology at Sendai Kosei Hospital)
Business Description: Research, development, manufacturing, and sales of next-generation endoscopic treatment anchor stents.
URL: https://koeda.co.jp
https://www.linkedin.com/company/koeda-inc/posts/?feedView=all
Contact Information:
For Inquiries Regarding This Matter:
KOEDA Inc. Public Relations Representative: Junko Otomo
Email: [email protected]
■ Background and Purpose of Funding: Accelerating domestic investigational clinical trials and US expansion
In 2025, KOEDA successfully completed First in Human (FIH) trials, considered the biggest hurdle in medical device development, proving the safety for clinical application in humans.
The funds raised this time will be used to accelerate the following business progress:
1. Conducting domestic investigational clinical trials: Completion of clinical trials for early manufacturing and sales approval and insurance coverage.
2. Strengthening regulatory affairs application and Quality Management System (QMS): Building a system for domestic launch and US FDA approval application.
3. Preparation for global expansion: Acquiring FDA approval and strengthening intellectual property strategy with an eye on entering the US market, our largest target.
■ About KOEDA Inc.: Transforming Digestive Medicine with the World's First 'Anchor Technology'
KOEDA is a startup developing endoscopic treatment devices (drainage for EUS-GBD/GJ) using the world's first 'anchor technology' for digestive diseases, including acute cholecystitis.
1. KOEDA's Ingenuity: Our proprietary 'anchor mechanism' physically secures organs. This simplifies procedures for digestive diseases like acute cholecystitis, shortens procedure times, and dramatically reduces the risk of complications.
2. High Technical Reliability: Having been selected multiple times for public funding such as AMED (Seeds A/C/Medical-Engineering Collaboration) and JST START, and having received the Japan Biliary Association Award, KOEDA has earned extremely high evaluations from specialized institutions and Key Opinion Leaders (KOLs).
■ Future Outlook: Roadmap Aiming for M&A EXIT by 2030
Leveraging this funding round, KOEDA aims to achieve the following milestones and pursue an M&A exit to a global med-tech company by 2030.
2027-2028: Obtain manufacturing and sales approval in Japan and launch. Introduction to major hospitals after insurance coverage.
2029: Obtain US FDA approval. Commence sales in the global market.
2030: Expand indications from gallbladder drainage (EUS-GBD) to gastrojejunostomy (EUS-GJ) and achieve business sale (M&A).
■ KOEDA Inc. Company Overview
Company Name: KOEDA Inc.
Representative: Toru Okuzono (Graduate of Tohoku University School of Medicine, Chief Director of Gastroenterology at Sendai Kosei Hospital)
Business Description: Research, development, manufacturing, and sales of next-generation endoscopic treatment anchor stents.
URL: https://koeda.co.jp
https://www.linkedin.com/company/koeda-inc/posts/?feedView=all
Contact Information:
For Inquiries Regarding This Matter:
KOEDA Inc. Public Relations Representative: Junko Otomo
Email: [email protected]